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Table S1. Single predictors selected for performance analysis with CYP21A2 variants. 
Single  
Predictors 
Description Website Ref. 
CADD  Integrative annotation built based on diverse genomic 
feature derived from surrounding sequence context, gene 
model annotation, evolutionary constraint, epigenetic 




ConSurf  Algorithm uses phylogenetic relationships among 
homologous sequences and the specific dynamics of the 
analyzed sequence with evolutionary models to estimate 
the evolutionary rates of the amino acid of the 
macromolecules and to map them onto the structure and/or 
sequence. 
https://consurf.tau.ac.il/ [2] 
DANN Deep neural network which takes non-linear relationships 
among features based on diverse genomic derived from 
surrounding sequence context, gene model annotation, 





FATHMM  Evolutionary conservation algorithm which uses 
homologous sequences with species-specific weighting to 





A statistical framework predictor which uses protein 
physicochemical characteristics of each amino acid position 






Machine learning-based to predict amino acid substitution 




Predict using evolutionary preservation data, measuring 






Machine learning algorithm for predicting SNVs in both non-




PolyPhen-2  It uses human protein evolutionary and structural data to 





PROVEN  Predict the functional effect through amino acid exchange 
evolutionary data and quality of the neighborhood 






Predicts through sequence homology algorithm assuming 





SNAP2  A neural network method based on machine learning to 
predict the variant effect in the molecular function through 
evolutionary and structural protein data with an amino acid 




SNPs&GO  Predict using evolutionary data, profile and gene ontology 
(biological process, cellular component and molecular 
function). When protein function is not available, it run 





Table S2. Performance of predictor tools.  18 
Predictor PPV NPV Se Sp Ac MCC AUC-ROC Dataset Ref. 
CADD  
  
93.6 57.1 0.85 
  
ClinVar (2015)  [1] 
DANN 
      
0.95 ClinVar (2014) [3] 
FATHMM (weighted) 0.85 0.8 0.78 0.87 0.82 0.65 
 
SwissVar (2012) [4] 
MAPP  
    
0.626-0.767 
 
Experimental studies [5] 
Meta-SNP 0.79 0.8 0.8 0.79 0.79 0.59 0.86 SwissVar (2009-2012) [14] 




84.9 ClinVar32 (2015)  and UniProt80 (2015) [6] 
PANTHER-PSEP 
      
0.721 Derived from SwissVar [7] 





0.79 Mutations on the genes BRCA1, MSH2, MLH1 and TP53 [15] 
PredictSNP  
    
0.642 0.281 0.7 Protein Mutant Database (07Mar26) [16] 
PredictSNP2 
    




   
UniProt human protein  [10] 
SNPs&GO 0.83 0.8 0.78 0.85 0.82 0.63 
 
Derived from Swiss-Prot (2008) [13] 
SIFT 4G 
  
0.8 0.735 0.7732 0.53 
 
UniRef90 (2011) [11] 
SNAP2  
    
0.688 0.24 
 
Data set consisting of 9,657 variants from 678 human proteins [12] 
SNP&GO3d 0.84 0.86 0.87 0.83 0.85 0.7 0.92 Derived from Swiss-Prot (2009) [18] 
*Data from an article recommended on the original developer article. PPV, positive predictive value; NPV, negative predictive value;  Se, sensibility; Sp, specificity; Ac, accuracy; MCC, Matthews' 19 
correlation coefficient test.20 
Table S3..List of the 103 single nucleotide variants (SNVs) on CYP21A2 gene selected to test the 21 
performance of predictor tools. SNVs are grouped into classical (enzyme activity < 10%), non-22 
classical (between 10 and 78 %) and neutral (> 78 %) groups. The enzyme activity levels of both 23 
21-hydroxylase substrates - 17-hydroxyprogesterone and progesterone - were obtained from 24 
the original paper of the functional characterization. The phenotype was obtained from either 25 
the same paper or the original description of the new SNV. a Shows the percentage of enzyme 26 
activity measured for the conversion of both 21-hydroxylase substrates, considering as 100 % 27 
the 21-hydroxylase wild type activity. 17OHP: 17-hydroxyprogesterone. SW: salt wasting. SV: 28 
simple-virilizing. NC: non-classical. ND: non-determinate. 29 
    CYP21A2 Activity in vitro     
Group NP_000491.4 17OHPa  SD (±) Progesterone SD (±)  Phenotype  Publication 
CL p.P31Q 0.2 0.2 0 0 SW [19] 
  p.G57R 0.7 ND 1.4 ND SV [20] 
  p.G65E 0 ND 0 ND SW [21] 
  p.I78T 3 2 5 3 SV [22] 
 p.G91V 0 ND 0 ND SW [23] 
  p.L108R 0.4 ND 0.3 ND SW [20] 
  p.S114F 4 1 4 2 SV [24] 
  p.L123P 1.42 2.13 -1.86 5.19 SW [25] 
  p.V140E 0.7 1.3 0.5 0.6 SW [26]  





  p.C148R 4.3 0.9 3.6ny 1.8 SV-NC [26] 
  p.L167P 0.3 0.06 0.4 0.6 SW [27] 
  p.L168P 0.7 ND 0.4 ND SW [28] 
  p.C170R 0.1 0.02 0 2 SW [29] 
  p.I172N 0.7 0.3 0.6 0.03 SV [30] 
  p.I173N 4.3 1.7 4.4 1.8 SV [28] 
  p.G179R 0.4 0.5 0 0.6 SW [29] 
  p.R234G 8 2 2 1 SV-NC [31] 
  p.I237N 1 0.7 2.4 1.4 SV [32] 
  p.V238E 0 0 0.1 0.3 SW [32] 
  p.V282G 3.9 1.7 3.9 2 SV [33] 
  p.H283N 1.6 6 2.7 5 SW [34] 
  p.G292C 0 ND 0 ND SW [23] 
  p.G292R 0.5 0.7 0.7 0.2 SW [26] 
  p.G292S 0.8 0.4 0.8 0.4 SW [35] 
  p.G293D 0.5 0.2 0.7 0.4 SW [28] 
  p.L301F 9.5 6.4 4.4 2.5 SV [33] 
  p.W303S 3 0.3 3 0.5 SV-NC [36] 
  p.W303R 0.1 0.2 0 0.5 SW [29] 
  p.L309F 0.2 0.3 0.1 0.3 SW [26] 
  p.E321K 4.6 1.8 4.5 2.6 SV [28] 
  p.R342P 0.7 0.3 0.7 0.2 SV [30] 
  p.R342W 5 0.4 4 3 SV-NC [31] 
  p.E352K 1.1 0.5 1.2 0.3 SV [37] 
  p.R355H 0 ND 0 ND SW [23] 
  p.R357P 0.15 0.3 0.15 0.3 SW [38] 
  p.R357Q 0.65 0.44 1.1 0.94 SV [38] 
  p.R357W 0 ND 0 ND SW [39] 
  p.A363V 0 ND 0 ND SW [21] 
  p.G376S 1.6 0.8 0.7 0.7 SW [40] 
  p.L389R 1.1 0.6 ND ND SW [41] 
 
Continuation (Table S3) 
  
 
      
CL p.H393Q 2.5 0.6 2.2 0.6 SW [42] 
  p.R409C 1.3 0.5 
  
SW [20] 
  p.G425S 1.6 0.4 2 0.6 SV [28] 
  p.R427C 0 0.5 0 0.6 SW [29] 
  p.R427H 0.5 0.6 0.4 0.2 SW-SV [30] 
  p.L447P 0.5 0.6 0 0.1 SW-SV [30] 
  p.T451P 0.9 ND 0.9 ND SW [24] 
  p.P464L 2.6 0.8 3 0.5 SV [43] 
  p.R484P 1 0.07 2.2 0.9 SV [35] 
  p.R484Q 1.1 0.7 3.8 1.9 SV [27] 
  Mean 1.52   1.32       
  SD 2.00   1.61       
NC p.P31L 13 0.2 2 0.6 NC [31] 
  p.H63L 44.5 ND 20.7 ND NC [20] 
  p.P106L 62 9 64 12 NC [44] 
  p.H120R 31.6 8 32.5 7 NC [45] 
  p.K122Q 14 5 19.5 4 NC [46] 
  p.R133C 35.4 7.4 15.5 2.7 NC [47] 
  p.E141K 11.3 2.4 ND ND SW [41] 
  p.R150C 35.8 14.6 47.3 12.9 NC [47] 
  p.R150P 23.4 1.7 16.9 2 NC [48] 
  p.M151R 17.66 1.87 4.57 1.96 NC [25] 
  p.G179A 19 ND ND ND NC [23] 
  p.Y192H 37.1 7 25.8 9 NC [34] 
  p.I195N 33.2 9 46.7 10 NC [45] 
  p.R225W 51.9 9 45.6 8 NC [49] 
  p.I231T 63.1 22.3 70.6 17 NC [28] 
  p.R234K 15 ND 8.1 ND SV-NC [28] 
  p.V282L 18 3 18 5 NC [31] 
  p.M284V 16.2 9.3 19 6.8 NC [47] 
  p.V305M 46 18 26 10 NC [50] 
  p.F307V 63.23 5.5 64.17 7.98 SV-NC [51] 
  p.D323G 18 1.2 27 4.7 NC [36] 
  p.R340H 67.1 2.4 45.8 3.7 NC [52] 
  p.V359I 72 7 34 3 NC [53] 
  p.H366N 46.13 4.8 57.77 3.69 NC [51] 
  p.R367C 37 7 28 4 NC [31] 
  p.R370Q 82 6 63 4 NC [53] 
  p.R370W 45.8 1.8 48.5 17.1 NC [28] 
  p.D378Y 81 6 58 4 NC [53] 
  p.E381D 30 ND ND ND SW [54] 
  p.A392T 38.7 9.5 22.9 4.7 NC [55] 
  p.D408N 72.7 7 73.6 10 NC [49] 
  p.E432K 26.2 3.8 24.2 7.4 NC [47] 
  p.A435V 14 2 12 6 SV [22] 
  p.T451M 78 6 43 5 NC [24] 
  p.P454S 38 ND 22.4 3 NC [31] 
  p.L462P 55 8 40 2 NC [53] 
 p.M474I 85 7 66 12 NC [31] 
  p.R480L 75.5 15.7 79.6 12 NC-Normal [55] 
  p.P483S 61 6 54 2 NC [31] 
  Mean 42.94   37.41       
  SD 22.59   20.98       
 
Continuation (Table S3) 
          
Neutral  p.L13M 99 1 100 1 Normal [24] 
p.A16T 100 0 96 6 Normal- very 
mildNC 
[24] 
p.R17C 95 3 81 3 Normal- very 
mildNC 
[24] 
p.R103K 119.7 22.5 ND ND Normal [41] 
p.A160T 126.6 29.9 ND ND Normal [41] 
p.D184E 100 ND 100 ND Normal [56] 
p.S203G 85 2 81 3 Very mild NC [24] 
p.V212M 99.5 32.4 ND ND Normal [41] 
p.M240K 95.4 24.7 97.7 7.7 Normal [32] 
p.A266S 90 9 104 15 Normal [31] 
p.A266V 92 1.4 100 4.3 Normal [36] 
p.P268L 97 1 87 7 Normal [24] 
p.S269T 103 15 ND ND Normal [57] 
  Average 100.17   94.08       




Table S4. Result of 17 predictors for 51 classical single nucleotide variants (SNVs) on the CYP21A2 gene. The classical group has an enzyme activity of < 10% of the 33 
wild-type activity. The genomic SNV nomenclature is based on the human chromatin remodeling 38 (Chr38). Del: deleterious; N: Neutral; Pby: Probably; Psb: 34 
Possible; B: Benign; Dse: Disease; Efc: Effect; P-Del: Proxy-deleterious; P-N: Proxy-neutral; Dmg: Damaging; T: Tolerated; Ptg: Pathogenic; Csv: Conserved; V: 35 
Variable; NR: no result. 36 
Chr38 SNP Meta-
SNP 
PredictSNP PredictSNP2  S3Ds&GO CADD ConSurf DANN FATHMM MAPP MutPred2  PANTHER PhD-
SNPg  
PolyPhen2 PROVEAN  SIFT SNAP2 SNPs&GO 
g.32038514C>A p.P31Q Dse Del N Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc N; 
g.32038591G>A p.G57R Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32038616G>A p.G65E Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32038752T>C p.I78T N Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby N N N N 
g.32038791G>T p.G91V Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32039124T>G p.L108R Dse Del N Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32039142C>T p.S114F Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby B Pby Del Del Efc Dse 
g.32039169T>C p.L123P Dse Del N Dse P-Del Csv Del T Del Del Pby Ptg Pby Del Del Efc Dse 
g.32039220T>A p.V140E Dse Del N Dse P-Del Csv Del T Del Del Pby Ptg Pby Del Del Efc Dse 
g.32039229T>C p.L143P Dse Del N Dse P-Del Csv Del T Del Del Pby Ptg Pby N N N Dse 
g.32039243T>C p.C148R N N N N P-Del Csv N Dmg Del Del Pby Ptg Psb  Del N N N 
g.32039408T>C p.L167P Dse Del N Dse P-Del V  Del T Del Del Pby Ptg Pby Del Del Efc Dse 
g.32039411T>C p.L168P Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby B Pby N N N Dse 
g.32039416T>C p.C170R Dse Del N Dse P-Del Csv Del Dmg Del Del Pby B Pby Del Del Efc Dse 
g.32039423T>A p.I172N Dse Del N Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32039426T>A p.I173N Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
Chr38 SNP Meta-
SNP 
PredictSNP PredictSNP2  S3Ds&GO CADD ConSurf DANN FATHMM MAPP MutPred2  PANTHER PhD-
SNPg  
PolyPhen2 PROVEAN  SIFT SNAP2 SNPs&GO 
g.32039443G>A p.G179R Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32039797A>G p.R234G Dse N N Dse P-Del Csv Del T N Del Pby B Pby Del Del Efc Dse 
g.32039807T>A p.I237N Dse Del N N P-Del V  Del T Del Del Pby Ptg Psb  Del Del Efc Dse 
g.32039810T>A p.V238E Dse Del N Dse P-Del Csv Del T Del Del Pby Ptg Psb  Del Del Efc Dse 
g.32040111T>G p.V282G Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040113C>A p.H283N Dse N N Dse P-Del Csv Del Dmg N N Pby Ptg Pby Del Del N Dse 
g.32040140G>A p.G292S Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040140G>C p.G292R Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040140G>T p.G292C Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040144G>A p.G293D Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040167C>T p.L301F Dse Del Del Dse P-Del Csv Del Dmg N Del Pby B Pby Del Del Efc Dse 
g.32040173T>C p.W303R Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040174G>C p.W303S Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040191C>T p.L309F N N Del N P-Del Csv Del Dmg N N Pby B Pby Del Del N N 
g.32040427G>A p.E321K Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040490C>T p.R342W Dse Del N Dse P-Del Csv Del Dmg N Del Pby Ptg Pby Del Del Efc Dse 
g.32040491G>C p.R342P Dse Del N Dse P-Del Csv Del T Del Del Pby B Pby Del Del Efc Dse 
g.32040520G>A p.E352K Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040530G>A p.R355H Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Psb  Del Del Efc Dse 
Continuation (Table S4) 
Chr38 SNP Meta-
SNP 
PredictSNP PredictSNP2  S3Ds&GO CADD ConSurf DANN FATHMM MAPP MutPred2  PANTHER PhD-
SNPg  
PolyPhen2 PROVEAN  SIFT SNAP2 SNPs&GO 
g.32040535C>T p.R357W Dse Del N Dse P-Del Csv Del T N Del Pby Ptg Pby Del Del Efc Dse 
g.32040536G>A p.R357Q Dse Del Del Dse P-Del Csv Del Dmg N N Pby Ptg Pby Del Del Efc Dse 
g.32040536G>C p.R357P Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040554C>T p.A363V N N N Dse P-Del Csv Del T N N Pby Ptg Pby N N N N 
g.32040675G>A p.G376S Dse Del Del Dse P-Del Csv Del Dmg N Del Pby Ptg Pby Del Del Efc Dse 
g.32040715T>G p.L389R Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040728C>G p.H393Q N N N Dse P-Del Csv Del T N Del Pby B B Del Del Efc N 
g.32040871C>T p.R409C Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Psb  Del Del Efc Dse 
g.32040919G>A p.G425S Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040925C>T p.R427C Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040926G>A p.R427H Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040986T>C p.L447P Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby B Pby Del Del Efc Dse 
g.32040997A>C p.T451P Dse Del N N P-Del Csv Del T Del Del Pby Ptg Psb  Del Del N N 
g.32041037C>T p.P464L N N Del N P-Del Csv Del Dmg Del N Pby Ptg Pby Del Del N N 
g.32041097G>A p.R484Q Dse Del Del N P-Del Csv Del Dmg N Del Pby Ptg Pby Del Del Efc N 
g.32041097G>C p.R484P Dse Del N N P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
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Continuation (Table S4) 
Table S5. Result of 17 predictors for 39 non-classical single nucleotide variants (SNVs) on the CYP21A2. The non-classical group has an enzyme activity between 39 
>10% and < 78% of the wild-type activity. The genomic SNV nomenclature is based on the human chromatin remodeling 38 (Chr38). Del: deleterious; N: Neutral; 40 
Pby: Probably; Psb: Possible; B: Benign; Dse: Disease; Efc: Effect; P-Del: Proxy-deleterious; P-N: Proxy-neutral; Dmg: Damaging; T: Tolerated; Ptg: Pathogenic; Csv: 41 
Conserved; V: Variable; NR: no result. 42 
Chr38 SNP Meta-
SNP 
PredictSNP PredictSNP2  S3Ds&GO CADD ConSurf DANN FATHMM MAPP MutPred2  PANTHER PhD-
SNPg  
PolyPhen2 PROVEAN  SIFT SNP2 SNPs&GO 
g.32038514C>T p.P31L N N N N P-Del Csv N Dmg Del Del Pby Ptg B N N N N 
g.32038610A>T p.H63L Dse N N N P-Del V  N T Del Del Pby B B N N Efc N 
g.32039118C>T p.P106L N N N N P-N V  N T N N Pby B B N N Efc N 
g.32039160A>G p.H120R N N N N P-Del Csv Del Dmg Del N Pby Ptg Pby Del Del Efc N 
g.32039165A>C p.K122Q Dse Del N N P-Del Csv Del Dmg Del N Pby Ptg Pby Del Del Efc N 
g.32039198C>T p.R133C Dse Del N Dse P-Del V  Del T N N Pby Ptg Pby Del Del Efc Dse 
g.32039222G>A p.E141K N N N N P-Del V  Del T N Del Pby Ptg Psb N N N N 
g.32039356C>T p.R150C N N Del Dse P-Del Csv Del Dmg N N Pby B Pby N N N N 
g.32039357G>C p.R150P Dse Del N Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby N N N Dse 
g.32039360T>G p.M151R Dse Del N Dse P-Del Csv Del Dmg Del Del Pby Ptg Psb  Del Del Efc Dse 
g.32039444G>C p.G179A Dse Del Del Dse P-Del Csv Del Dmg Del N Pby Ptg Pby Del Del Efc Dse 
g.32039570T>C p.Y192H N N N N P-N Csv N T N N Pby B B N N N N 
g.32039580T>A p.I195N N N N Dse P-Del Csv Del T N Del Pby Ptg Pby N Del Efc Dse 
g.32039770C>T p.R225W Dse N N N P-N V  N T N Del Pby B B Del N N N 
g.32039789T>C p.I231T N N N N P-Del V  Del T N N Pby B B N Del N N 
g.32039798G>A p.R234K N N N Dse P-Del Csv Del Dmg N N Pby Ptg Pby N Del Efc N 
Chr38 SNP Meta-
SNP 
PredictSNP PredictSNP2  S3Ds&GO CADD ConSurf DANN FATHMM MAPP MutPred2  PANTHER PhD-
SNPg  
PolyPhen2 PROVEAN  SIFT SNP2 SNPs&GO 
g.32040110G>T p.V282L N N N N P-Del Csv Del Dmg N N Pby Ptg Psb N N N N 
g.32040116A>G p.M284V N N Del Dse P-Del Csv Del Dmg N N Pby Ptg Pby Del Del Efc Dse 
g.32040179G>A p.V305M Dse N Del N P-Del Csv Del Dmg N N Pby B Pby N Del N N 
g.32040185T>G p.F307V N N N Dse P-Del Csv Del Dmg N Del Pby B Pby Del Del N Dse 
g.32040434A>G p.D323G Dse Del N N P-Del V  Del T Del Del Pby B Pby Del Del N N 
g.32040485G>A p.R340H Dse Del Del N P-Del Csv Del Dmg N Del Pby B Pby Del Del Efc Dse 
g.32040541G>A p.V359I N N N N P-Del Csv Del Dmg N N Pby B Psb N Del N N 
g.32040562C>A p.H366N Dse Del N Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc N 
g.32040565C>T p.R367C N N N N P-Del Csv Del T N Del Pby B B N N N N 
g.32040574C>T p.R370W Dse Del N Dse P-Del Csv Del T Del N Pby B Pby Del Del Efc Dse 
g.32040575G>A p.R370Q N N N N P-Del Csv Del T N N Pby B Psb N N N N 
g.32040681G>T p.D378Y N N N N P-Del Csv Del T N Del Pby B Psb Del N N N 
g.32040692G>C p.E381D N N Del N P-Del Csv Del Dmg N N Pby B B N Del Efc N 
g.32040723G>A p.A392T N N Del Dse P-Del Csv Del Dmg Del N Pby B Pby N N N Dse 
g.32040771G>A p.D408N N N Del N P-Del Csv Del Dmg N N Pby Ptg Pby N Del N N 
g.32040940G>A p.E432K Dse Del Del Dse P-Del Csv Del Dmg N Del Pby Ptg Pby Del Del Efc Dse 
g.32040950C>T p.A435V Dse Del Del Dse P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del Efc Dse 
g.32040998C>T p.T451M N Del N N P-Del Csv Del T Del N Pby Ptg Psb Del Del N N 
g.32041006C>T p.P454S N Del Del N P-Del Csv Del Dmg N N Pby Ptg Pby Del Del N N 
Continuation (Table S5) 
Chr38 SNP Meta-
SNP 
PredictSNP PredictSNP2  S3Ds&GO CADD ConSurf DANN FATHMM MAPP MutPred2  PANTHER PhD-
SNPg  
PolyPhen2 PROVEAN  SIFT SNP2 SNPs&GO 
g.32041031T>C p.L462P Dse Del Del N P-Del Csv Del Dmg Del Del Pby Ptg Pby Del Del N N 
g.32041068G>T p.M474I N N N N P-N V  N T N N Pby B B Del N N N 
g.32041085G>T p.R480L N N N N P-Del V  Del T N N Pby B B N N N N 
g.32041093C>T p.P483S N N Del N P-Del Csv Del Dmg N N Pby Ptg Pby N Del Efc N 
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Continuation (Table S5) 
Table S6. Result of 17 predictors for 13 neutral single nucleotide variants (SNVs) on the CYP21A2 gene. The neutral group has the enzyme activity known as > 78% 45 
of the wild-type activity. The genomic SNV nomenclature is based on the human chromatin remodeling 38 (Chr38). Del: deleterious; N: Neutral; Pby: Probably; 46 
Psb: Possible; Dse: Disease; Efc: Effect; P-Del: Proxy-deleterious; P-N: Proxy-neutral; Dmg: Damaging; T: Tolerated; Ptg: Pathogenic; B: Benign; Csv: Conserved; V: 47 
Variable; NR: no result. 48 
Chr38 SNP Meta-
SNP 
PredictSNP PredictSNP2  S3Ds&GO CADD ConSurf DANN FATHMM MAPP MutPred2  PANTHER PhD-
SNPg  
PolyPhen2 PROVEAN  SIFT SNP2 SNPs&GO 
g.32038459C>A p.L13M N N N NR P-Del NR Del T Del N NR B Pby N Del N N 
g.32038468G>A p.A16T N N N NR P-N NR N T N N NR B B N N N N 
g.32038471C>T p.R17C N N N NR P-N NR Del T N N NR B B N Del N N 
g.32039109G>A p.R103K N N N N P-N V  N T N N NR B B N N N N 
g.32039386G>A p.A160T N N N N P-N Csv N T N N Pby B B N N N N 
g.32039548C>G p.D184E N N N N P-N V  N T N N Pby B B N N N N 
g.32039603A>G p.S203G N N N N P-N V  N T N N Pby B B N N N N 
g.32039630G>A p.V212M N N N N P-N V  Del T N N Pby B B N N N N 
g.32039816T>A p.M240K N N N N P-Del V  N T N N Pby Ptg B N N N N 
g.32040062G>T p.A266S N N N N P-N V  N T N N Pby B B N N N N 
g.32040063C>T p.A266V N N N N P-N V  Del T Del N Pby B B N N N N 
g.32040069C>T p.P268L N N N NR P-N V  N T N N Pby B B N N N N 




1.  van der Velde, K.J.; de Boer, E.N.; van Diemen, C.C.; Sikkema-Raddatz, B.; Abbott, K.M.; 52 
Knopperts, A.; Franke, L.; Sijmons, R.H.; de Koning, T.J.; Wijmenga, C.; et al. GAVIN: 53 
Gene-Aware Variant INterpretation for Medical Sequencing. Genome Biology 2017, 18, 54 
doi:10.1186/s13059-016-1141-7. 55 
2.  Ashkenazy, H.; Abadi, S.; Martz, E.; Chay, O.; Mayrose, I.; Pupko, T.; Ben-Tal, N. ConSurf 56 
2016: An Improved Methodology to Estimate and Visualize Evolutionary Conservation 57 
in Macromolecules. Nucleic Acids Research 2016, 44, W344–W350, 58 
doi:10.1093/nar/gkw408. 59 
3.  Quang, D.; Chen, Y.; Xie, X. DANN: A Deep Learning Approach for Annotating the 60 
Pathogenicity of Genetic Variants. Bioinformatics 2015, 31, 761–763, 61 
doi:10.1093/bioinformatics/btu703. 62 
4.  Shihab, H.A.; Gough, J.; Cooper, D.N.; Stenson, P.D.; Barker, G.L.A.; Edwards, K.J.; Day, 63 
I.N.M.; Gaunt, T.R. Predicting the Functional, Molecular, and Phenotypic Consequences 64 
of Amino Acid Substitutions Using Hidden Markov Models. Human Mutation 2013, 34, 65 
57–65, doi:10.1002/humu.22225. 66 
5.  Stone, E.A.; Sidow, A. Physicochemical Constraint Violation by Missense Substitutions 67 
Mediates Impairment of Protein Function and Disease Severity. Genome Research 2005, 68 
15, 978–986, doi:10.1101/gr.3804205. 69 
6.  Pejaver, V.; Urresti, J.; Lugo-Martinez, J.; Pagel, K.A.; Lin, G.N.; Nam, H.J.; Mort, M.; 70 
Cooper, D.N.; Sebat, J.; Iakoucheva, L.M.; et al. Inferring the Molecular and Phenotypic 71 
Impact of Amino Acid Variants with MutPred2. Nature Communications 2020, 11, 72 
doi:10.1038/s41467-020-19669-x. 73 
7.  Tang, H.; Thomas, P.D. PANTHER-PSEP: Predicting Disease-Causing Genetic Variants 74 
Using Position-Specific Evolutionary Preservation. Bioinformatics 2016, 32, 2230–2232, 75 
doi:10.1093/bioinformatics/btw222. 76 
8.  Capriotti, E.; Fariselli, P. PhD-SNPg: A Webserver and Lightweight Tool for Scoring Single 77 
Nucleotide Variants. Nucleic Acids Research 2017, 45, W247–W252, 78 
doi:10.1093/nar/gkx369. 79 
9.  Adzhubei, I.; Jordan, D.M.; Sunyaev, S.R. Predicting Functional Effect of Human 80 
Missense Mutations Using PolyPhen‐2. Current Protocols in Human Genetics 2013, 76, 81 
doi:10.1002/0471142905.hg0720s76. 82 
10.  Choi, Y.; Sims, G.E.; Murphy, S.; Miller, J.R.; Chan, A.P. Predicting the Functional Effect 83 
of Amino Acid Substitutions and Indels. PLoS ONE 2012, 7, 84 
doi:10.1371/journal.pone.0046688. 85 
11.  Vaser, R.; Adusumalli, S.; Leng, S.N.; Sikic, M.; Ng, P.C. SIFT Missense Predictions for 86 
Genomes. Nature Protocols 2016, 11, 1–9, doi:10.1038/nprot.2015.123. 87 
12.  Hecht, M.; Bromberg, Y.; Rost, B. Better Prediction of Functional Effects for Sequence 88 
Variants. BMC Genomics 2015, 16, doi:10.1186/1471-2164-16-S8-S1. 89 
13.  Calabrese, R.; Capriotti, E.; Fariselli, P.; Martelli, P.L.; Casadio, R. Functional Annotations 90 
Improve the Predictive Score of Human Disease-Related Mutations in Proteins. Human 91 
Mutation 2009, 30, 1237–1244, doi:10.1002/humu.21047. 92 
14.  Capriotti, E.; Altman, R.B.; Bromberg, Y. Collective Judgment Predicts Disease-93 
Associated Single Nucleotide Variants. BMC genomics 2013, 14 Suppl 3, 94 
doi:10.1186/1471-2164-14-s3-s2. 95 
15.  Hicks, S.; Wheeler, D.A.; Plon, S.E.; Kimmel, M. Prediction of Missense Mutation 96 
Functionality Depends on Both the Algorithm and Sequence Alignment Employed. 97 
Human Mutation 2011, 32, 661–668, doi:10.1002/humu.21490. 98 
16.  Bendl, J.; Stourac, J.; Salanda, O.; Pavelka, A.; Wieben, E.D.; Zendulka, J.; Brezovsky, J.; 99 
Damborsky, J. PredictSNP: Robust and Accurate Consensus Classifier for Prediction of 100 
Disease-Related Mutations. PLoS Computational Biology 2014, 10, 101 
doi:10.1371/journal.pcbi.1003440. 102 
17.  Bendl, J.; Musil, M.; Štourač, J.; Zendulka, J.; Damborský, J.; Brezovský, J. PredictSNP2: A 103 
Unified Platform for Accurately Evaluating SNP Effects by Exploiting the Different 104 
Characteristics of Variants in Distinct Genomic Regions. PLoS Computational Biology 105 
2016, 12, doi:10.1371/journal.pcbi.1004962. 106 
18.  Capriotti, E.; Altman, R.B. Improving the Prediction of Disease-Related Variants Using 107 
Protein Three-Dimensional Structure. BMC Bioinformatics 2011, 12, doi:10.1186/1471-108 
2105-12-S4-S3. 109 
19.  Lajic, S.; Nikoshkov, A.; Holst, M.; Wedell, A. Effects of Missense Mutations and 110 
Deletions on Membrane Anchoring and Enzyme Function of Human Steroid 21-111 
Hydroxylase (P450c21); 1999; 112 
20.  Soardi, F.C.; Barbaro, M.; Lau, I.F.; Lemos-Marini, S.H. v.; Baptista, M.T.M.; Guerra-113 
Junior, G.; Wedell, A.; Lajic, S.; de Mello, M.P. Inhibition of CYP21A2 Enzyme Activity 114 
Caused by Novel Missense Mutations Identified in Brazilian and Scandinavian Patients. 115 
The Journal of Clinical Endocrinology & Metabolism 2008, 93, 2416–2420, 116 
doi:10.1210/jc.2007-2594. 117 
21.  Ohlsson, G.; Muller, J.; Skakkebaek, N.E.; Schwartz, M. Steroid 21-Hydroxylase 118 
Deficiency: Mutational Spectrum in Denmark, Three Novel Mutations, and in Vitro 119 
Expression Analysis. Human Mutation 1999, 13, 482–486, doi:10.1002/(SICI)1098-120 
1004(1999)13:6<482::AID-HUMU8>3.0.CO;2-0. 121 
22.  Krone, N.; Riepe, F.G.; Grötzinger, J.; Partsch, C.-J.; Sippell, W.G. Functional 122 
Characterization of Two Novel Point Mutations in the CYP21 Gene Causing Simple 123 
Virilizing Forms of Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. 124 
The Journal of Clinical Endocrinology & Metabolism 2005, 90, 445–454, 125 
doi:10.1210/jc.2004-0813. 126 
23.  Nunez, B.S.; Lobato, M.N.; White, P.C.; Meseguer, A. Functional Analysis of Four CYP21 127 
Mutations from Spanish Patients with Congenital Adrenal Hyperplasia. Biochemical and 128 
Biophysical Research Communications 1999, 262, 635–637, 129 
doi:10.1006/bbrc.1999.1271. 130 
24.  de Paula Michelatto, D.; Karlsson, L.; Lusa, A.L.G.; Silva, C.D.M.; Östberg, L.J.; Persson, 131 
B.; Guerra-Júnior, G.; Lemos-Marini, S.H.V. de; Barbaro, M.; de Mello, M.P.; et al. 132 
Functional and Structural Consequences of Nine CYP21A2 Mutations Ranging from Very 133 
Mild to Severe Effects. International Journal of Endocrinology 2016, 2016, 1–10, 134 
doi:10.1155/2016/4209670. 135 
25.  Massimi, A.; Malaponti, M.; Federici, L.; Vinciguerra, D.; Manca Bitti, M.; Vottero, A.; 136 
Ghizzoni, L.; Maccarrone, M.; Cappa, M.; Bernardini, S.; et al. Functional and Structural 137 
Analysis of Four Novel Mutations of CYP21A2 Gene in Italian Patients with 21-138 
Hydroxylase Deficiency. Hormone and Metabolic Research 2014, 46, 515–520, 139 
doi:10.1055/s-0034-1371864. 140 
26.  Barbaro, M.; Soardi, F.C.; Palandi de Mello, M.; Wedell, A.; Lajic, S. Functional Studies of 141 
CYP21A2 Mutants Complement Structural and Clinical Predictions of Disease Severity in 142 
CAH. Clinical Endocrinology 2012, 76, 766–768, doi:10.1111/j.1365-2265.2011.04275.x. 143 
27.  Robins, T.; Bellanne-Chantelot, C.; Barbaro, M.; Cabrol, S.; Wedell, A.; Lajic, S. 144 
Characterization of Novel Missense Mutations in CYP21 Causing Congenital Adrenal 145 
Hyperplasia. Journal of Molecular Medicine 2007, 85, 247–255, doi:10.1007/s00109-146 
006-0121-x. 147 
28.  Tardy, V.; Menassa, R.; Sulmont, V.; Lienhardt-Roussie, A.; Lecointre, C.; Brauner, R.; 148 
David, M.; Morel, Y. Phenotype-Genotype Correlations of 13 Rare CYP21A2 Mutations 149 
Detected in 46 Patients Affected with 21-Hydroxylase Deficiency and in One Carrier. 150 
Journal of Clinical Endocrinology and Metabolism 2010, 95, 1288–1300, 151 
doi:10.1210/jc.2009-1202. 152 
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